Home » Stocks » BPTS

Biophytis S.A. (BPTS)

Stock Price: $11.89 USD 0.64 (5.69%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 134.10M
Revenue (ttm) n/a
Net Income (ttm) -20.80M
Shares Out 11.28M
EPS (ttm) -1.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $11.89
Previous Close $11.25
Change ($) 0.64
Change (%) 5.69%
Day's Open 11.46
Day's Range 11.46 - 11.89
Day's Volume 180
52-Week Range 10.39 - 18.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

All ordinary and extraordinary resolutions have been adopted All ordinary and extraordinary resolutions have been adopted

1 month ago - GlobeNewsWire

PARIS and CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slo...

1 month ago - GlobeNewsWire

PARIS and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slo...

1 month ago - GlobeNewsWire

PARIS and CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that are aim...

1 month ago - GlobeNewsWire

PARIS and CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeut...

2 months ago - GlobeNewsWire

PARIS and CAMBRIDGE, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“BIOPHYTIS” or the “company”), a clinical-stage biotechnology company focuse...

2 months ago - GlobeNewsWire

PARIS and CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused...

2 months ago - GlobeNewsWire

Legally required documents for shareholders' votes are available on Biophytis website

3 months ago - GlobeNewsWire

PARIS and CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused ...

3 months ago - GlobeNewsWire

PARIS and CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqGS: BPTS; Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeuti...

3 months ago - GlobeNewsWire

PARIS and CAMBRIDGE, Mass., Feb. 15, 2021 (GLOBE NEWSWIRE) -- Biophytis (NasdaqCM: BPTS; Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on t...

3 months ago - GlobeNewsWire

Biophytis (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage...

4 months ago - GlobeNewswire

Biophytis, a French Phase 2 biotech developing therapies for COVID-related complications and age-related diseases, filed on Tuesday with the SEC to raise up to $15 million in an initial public offering....

4 months ago - NASDAQ

Biophytis S.A. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

About BPTS

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Our goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need. The global population of people over the age of 60 is expected to double from approximate... [Read more...]

Industry
Biotechnology
IPO Date
Feb 10, 2021
CEO
Stanislas Veillet
Employees
25
Stock Exchange
NASDAQ
Ticker Symbol
BPTS
Full Company Profile

Financial Performance

Financial numbers in millions EUR.
Financial Statements